Picard Medical / SynCardia Announce Successful Four-Year Bridge to Transplant with SynCardia Total Artificial Heart Support
Rhea-AI Summary
Picard Medical (NYSE American: PMI) announced a 29-year-old patient received a donor heart after 1,636 days supported continuously by the SynCardia Total Artificial Heart, implanted September 2, 2021, with transplant on February 24, 2026. The device replaces both ventricles and all four valves as a bridge to transplant.
The company noted >2,100 worldwide SynCardia implants and that longest documented support has exceeded eight years; individual outcomes may vary.
Positive
- 1,636-day continuous bridge to transplant
- Device enabled patient to await transplant while living outside hospital
- More than 2,100 SynCardia implants worldwide
- Longest documented device support exceeded 8 years
Negative
- Single-patient outcome; not evidence of broader efficacy across all patients
News Market Reaction – PMI
In the Mar 17 session, PMI declined 10.24%, reflecting a significant negative market reaction. Argus tracked a trough of -4.4% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 13 | Media spotlight | Positive | -4.7% | FOX Business feature on SynCardia Total Artificial Heart and next‑gen platform. |
| Mar 12 | Business update | Positive | -4.7% | Announcement of Annual Business Update webcast reviewing FY2025 and Q4 results. |
| Mar 02 | Conference data | Positive | +0.0% | New clinical and preclinical data on SynCardia and Emperor at THT 2026. |
| Feb 26 | Training event | Positive | -0.9% | Hands-on clinical training day at THT 2026 for SynCardia therapy use. |
| Feb 23 | Surgical training | Positive | -7.1% | Invitation-only surgical training program for leading heart transplant centers. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinically oriented and visibility-focused announcements often coincided with flat to negative next-day moves, suggesting a pattern of weak price follow-through on positive news.
Over the past month, Picard Medical has focused on raising clinical visibility for the SynCardia Total Artificial Heart, including training events and conference presentations on Feb 23, Feb 26, and Mar 2, plus media and business-update announcements on Mar 12–13. Despite generally positive clinical and strategic messaging, four of five prior news days saw negative next‑day moves, indicating investors have reacted cautiously to similar communications.
Key Terms
total artificial heart medical
biventricular heart failure medical
left ventricular assist device medical
hemodynamic stability medical
mechanical circulatory support medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
29-year-old patient supported for more than 1,600 days on the SynCardia Total Artificial Heart before receiving a donor heart transplant
TUCSON, Ariz., March 17, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that a 29-year-old patient successfully received a donor heart transplant after living for more than four years supported entirely by the SynCardia Total Artificial Heart.
The patient was implanted with the SynCardia Total Artificial Heart on September 2, 2021, after developing severe biventricular heart failure. The device replaced the pumping function of both sides of the heart, maintaining circulation while the patient awaited a donor organ. After 1,636 days of continuous artificial heart support, the patient underwent a successful heart transplant on February 24, 2026.
“The challenge in advanced heart failure is often the time required to find a suitable donor organ,” said Patrick NJ Schnegelsberg, Chief Executive Officer of Picard Medical. “This case demonstrates how the SynCardia Total Artificial Heart can sustain critically ill patients for extended periods, allowing them to live at home while awaiting heart transplantation.”
Total artificial heart therapy is indicated as a bridge to transplant for patients with irreversible biventricular heart failure who cannot be supported with isolated left ventricular assist device therapy. By replacing both ventricles and all four native heart valves, the SynCardia Total Artificial Heart restores circulation and hemodynamic stability while patients await donor organ availability.
More than 2,100 SynCardia Total Artificial Heart implants have been performed worldwide in patients with advanced biventricular heart failure, with the longest documented patient support exceeding eight years on device.
While individual outcomes may vary, extended duration support cases continue to inform clinical practice and illustrate the potential for long term mechanical circulatory support in carefully selected patients.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the circulatory functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available on the SEC’s website, http://www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
